Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly



Status:Archived
Conditions:Skin Cancer, Endocrine
Therapuetic Areas:Endocrinology, Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:February 2011
End Date:April 2013

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

PHASE IIIB, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF AN 84-MG OCTREOTIDE SUBCUTANEOUS HYDROGEL IMPLANT IN SUBJECTS WITH ACROMEGALY


This is a long term study to evaluate the safety, tolerability and efficacy of an Octreotide
Implant in patients that were previously treated with an Octreotide implant.


Evaluation on the long-term safety and tolerability, including local tolerability of the
implant site, of the 84-mg octreotide hydrogel implant in subjects with acromegaly who had
been successfully treated with the 84-mg octreotide hydrogel implant in the Phase III study
IP107-001.


We found this trial at
6
sites
Clinical Trial Facility
Lima, Ohio
1904
mi
from 91732
Lima, OH
Click here to add this to my saved trials
Clinical Trial Facility
Centralia, Illinois
1630
mi
from 91732
Centralia, IL
Click here to add this to my saved trials
Clinical Trial Facility
Chevy Chase, Maryland 20815
2278
mi
from 91732
Chevy Chase, MD
Click here to add this to my saved trials
Clinical Trial Facility
Denver, Colorado
817
mi
from 91732
Denver, CO
Click here to add this to my saved trials
Clinical Trial Facility
Medford, Oregon
627
mi
from 91732
Medford, OR
Click here to add this to my saved trials
Clinical Trial Facility
Mountlake Terrace, Washington
973
mi
from 91732
Mountlake Terrace, WA
Click here to add this to my saved trials